6/13
07:09 am
mtnb
Matinas BioPharma's Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin [Yahoo! Finance]
Medium
Report
Matinas BioPharma's Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin [Yahoo! Finance]
6/13
07:00 am
mtnb
Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin
Medium
Report
Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin
5/16
07:06 am
mtnb
New In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024 [Yahoo! Finance]
Low
Report
New In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024 [Yahoo! Finance]
5/16
07:00 am
mtnb
New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024
Low
Report
New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024
5/9
04:12 pm
mtnb
Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update [Yahoo! Finance]
Low
Report
Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update [Yahoo! Finance]
5/9
04:05 pm
mtnb
Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update
Low
Report
Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update
5/7
08:00 am
mtnb
Matinas BioPharma’s LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual Meeting
Medium
Report
Matinas BioPharma’s LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual Meeting
5/2
07:00 am
mtnb
Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024
Low
Report
Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024
4/30
08:17 am
mtnb
In Vivo Efficacy of Matinas BioPharma's Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy [Yahoo! Finance]
Low
Report
In Vivo Efficacy of Matinas BioPharma's Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy [Yahoo! Finance]
4/30
08:17 am
mtnb
Lundquist Investigator Dr. Ashraf Ibrahim Is the Lead Author in the Landmark Study on Pioneering Oral Fungal Infection Treatment Showing Promise in Preclinical Trials [Yahoo! Finance]
Low
Report
Lundquist Investigator Dr. Ashraf Ibrahim Is the Lead Author in the Landmark Study on Pioneering Oral Fungal Infection Treatment Showing Promise in Preclinical Trials [Yahoo! Finance]
4/30
08:00 am
mtnb
In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy
Medium
Report
In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy
4/3
08:42 am
mtnb
Matinas BioPharma Prices $10 Million Registered Direct Offering [Yahoo! Finance]
High
Report
Matinas BioPharma Prices $10 Million Registered Direct Offering [Yahoo! Finance]
4/3
08:30 am
mtnb
Matinas BioPharma Prices $10 Million Registered Direct Offering
High
Report
Matinas BioPharma Prices $10 Million Registered Direct Offering
4/1
02:34 pm
mtnb
Matinas BioPharma Holdings, Inc. (AMEX:MTNB) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
High
Report
Matinas BioPharma Holdings, Inc. (AMEX:MTNB) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/27
04:09 pm
mtnb
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update [Yahoo! Finance]
Medium
Report
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update [Yahoo! Finance]
3/27
04:05 pm
mtnb
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
Medium
Report
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
3/25
08:06 am
mtnb
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation [Yahoo! Finance]
Medium
Report
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation [Yahoo! Finance]
3/25
08:00 am
mtnb
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
Low
Report
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
3/22
09:19 am
mtnb
Three Patients with Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response [Yahoo! Finance]
High
Report
Three Patients with Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response [Yahoo! Finance]
3/22
09:15 am
mtnb
Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response
Low
Report
Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response
3/22
06:36 am
mtnb
Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards [Yahoo! Finance]
Medium
Report
Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards [Yahoo! Finance]
3/22
06:30 am
mtnb
Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards
Medium
Report
Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards